vipadenant

Showing 1 posts of 1 posts found.

Busy week at Juno Therapeutics ends with takeover of RedoxTherapies

July 15, 2016
Medical Communications, Research and Development, Sales and Marketing juno therapeutics, redoxtherapies, takeover, vipadenant

Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.

Latest content